NDA 020690 · Eisai INC
Aricept
Donepezil Hydrochloride · Oral
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Dec 18, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1996
Nov 25, 1996
Approved uses
2
Original approval plus efficacy supplements
Registered trials
332
55 Phase 3, 12 recruiting
FAERS reports
19,997
14,679 serious, 3,033 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 30, 2021.
ARICEPT is indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s disease. ARICEPT is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s Disease ( 1 )
Mechanism: Current theories on the pathogenesis of the cognitive signs and symptoms of Alzheimer’s disease attribute some of them to a deficiency of cholinergic neurotransmission. Donepezil hydrochloride is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. There is no evidence that donepezil alters the course of the underlying dementing process.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 13, 2006 Supplement 26 · Efficacy LetterLabel
- Nov 25, 1996 Original approval · Type 1 - New Molecular Entity · priority review Review
2 products under this application
- ARICEPT · DONEPEZIL HYDROCHLORIDE 10MG · TABLET, ORAL · Prescription · TE AB
- ARICEPT · DONEPEZIL HYDROCHLORIDE 5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Donepezil" as an intervention, any sponsor and status, largest first.
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)Pivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05976152 · 3,200 participants (planned) · Start Apr 2024 · Primary completion Dec 2026
Drug: dl-3-butylphthalide; dl-3-butylphthalide placebo · For: Stroke; Post-stroke Cognitive Impairment (PSCI)
Sites: Dandong, China
- Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's DiseasePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00348309 · 1,496 participants · Start Jul 6, 2006 · Primary completion Jan 1, 2009
Drug: Rosiglitazone Extended Release 2mg; Rosiglitazone Extended Release 8mg · For: Alzheimer's Disease
Sites: Litchfield Park, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 249 sites in all
- Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's DiseasePivotal-lookingCompleted
Eisai Inc.Eisai
NCT00478205 · 1,467 participants · Start Jun 2007 · Primary completion Jun 2009
Drug: Aricept (donepezil SR 23 mg); Aricept (donepezil IR 10 mg) · For: Alzheimer's Disease
Sites: Hickory, North Carolina
- Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's DiseasePivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT02079246 · 1,463 participants · Start Apr 7, 2014 · Primary completion Jul 6, 2017
Drug: Idalopirdine 60 mg · For: Alzheimer's Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 258 sites in all
- Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET StudyPivotal-lookingCompleted
Axovant Sciences Ltd.Industry
NCT02585934 · 1,315 participants · Start Oct 2015 · Primary completion Sep 2017
Drug: RVT-101; Placebo · For: Alzheimer's Disease
Sites: Phoenix, Arizona; Tucson, Arizona; Encino, California · 197 sites in all
- Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)Pivotal-lookingNot yet recruiting
University Hospital, BordeauxAcademic, hospital or other
NCT03454646 · 1,205 participants (planned) · Start Jun 1, 2024 · Primary completion Apr 27, 2027
Drug: cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine) · For: Alzheimer Disease; Cholinesterase Inhibitors
Sites: Amiens, France; Angers, France; Bastia, France · 31 sites in all
- 12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET ExtensionPivotal-lookingTerminated
Axovant Sciences Ltd.Industry
NCT02586909 · 1,099 participants · Start Apr 26, 2016 · Primary completion Mar 12, 2018
Drug: RVT-101 35 mg tablets · For: Alzheimer's Disease
Sites: Phoenix, Arizona; Tucson, Arizona; Rancho Mirage, California · 169 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fall1,630
- confusional state1,125
- dizziness1,008
- death967
- nausea958
- diarrhoea943
- fatigue934
- asthenia847
- drug ineffective804
- hallucination779
- somnolence761
- vomiting697
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,108 |
| 2005 | 793 |
| 2006 | 806 |
| 2007 | 578 |
| 2008 | 692 |
| 2009 | 710 |
| 2010 | 948 |
| 2011 | 952 |
| 2012 | 956 |
| 2013 | 748 |
| 2014 | 853 |
| 2015 | 1,211 |
| 2016 | 1,076 |
| 2017 | 1,098 |
| 2018 | 920 |
| 2019 | 816 |
| 2020 | 706 |
| 2021 | 661 |
| 2022 | 888 |
| 2023 | 864 |
| 2024 | 916 |
| 2025 | 957 |
| 2026 | 739 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Aricept (Donepezil HCl)
2024 spending
$1.2M
Beneficiaries
368
1,403 claims
Per beneficiary
$3,216
$15.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,783,382 |
| 2021 | $2,194,177 |
| 2022 | $1,964,518 |
| 2023 | $1,589,638 |
| 2024 | $1,183,465 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Evaluating the efficacy and safety of Alzheimer's disease drugs: A meta-analysis and systematic review.
Chen Y, Lai M, Tao M · Medicine (Baltimore) 2024 · Meta-Analysis, Systematic Review
- Donepezil for dementia due to Alzheimer's disease.
Birks JS, Harvey RJ · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Cholinesterase inhibitors for Alzheimer's disease.
Birks J · Cochrane Database Syst Rev 2006 · Meta-Analysis, Systematic Review
- Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.
Stinton C, McKeith I, Taylor JP, et al. · Am J Psychiatry 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Hansen RA, Gartlehner G, Webb AP, et al. · Clin Interv Aging 2008 · Comparative Study, Meta-Analysis
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
Rogers SL, Farlow MR, Doody RS, et al. · Neurology 1998 · Clinical Trial, Multicenter Study
Sponsor: Eisai
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.